Last update 27 Mar 2025

Cosyntropin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
1-24-Corticotropin - Travere Therapeutics, ACTH (1-24) - Travere Therapeutics, adrenocorticotropic hormone 1-24
+ [21]
Action
agonists
Mechanism
ACTH receptor agonists(Melanocortin receptor 2 agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (03 Sep 1969),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC138H214N40O33S
InChIKeyXDSGCNRPXJYVQS-GLMYKROOSA-N
CAS Registry60189-34-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Adrenal Insufficiency
United States
22 Apr 1970
Asthma
Japan
03 Sep 1969
Epilepsy
Japan
03 Sep 1969
Nephrotic Syndrome
Japan
03 Sep 1969
Rheumatoid Arthritis
Japan
03 Sep 1969
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fatigue Syndrome, ChronicPhase 3
United States
22 May 2015
Multiple sclerosis relapsePhase 3
United States
22 May 2015
Multiple Sclerosis, Relapsing-RemittingPhase 3
United States
22 May 2015
Muscular Dystrophy, DuchennePhase 2
United States
27 Jul 2018
Muscular Dystrophy, DuchennePhase 2
Bulgaria
27 Jul 2018
Muscular Dystrophy, DuchennePhase 2
Israel
27 Jul 2018
Muscular Dystrophy, DuchennePhase 2
Italy
27 Jul 2018
Muscular Dystrophy, DuchennePhase 2
Mexico
27 Jul 2018
Muscular Dystrophy, DuchennePhase 2
Serbia
27 Jul 2018
Muscular Dystrophy, DuchennePhase 2
Spain
27 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
59
(ACTH)
tpbgujnvft = dzclbxowko cqjhqnfpna (qkqifdqxho, nskdldtuzy - arjxcyorgv)
-
25 Mar 2025
Placebo
(Placebo)
tpbgujnvft = rtibrsmcho cqjhqnfpna (qkqifdqxho, ztmcbfmzib - zrekkpmzhy)
Not Applicable
-
-
fiebjxmgnu(rzdxdnyuoy) = efgisjoben gadlgobkca (abhntdzymp )
-
01 Jun 2024
fiebjxmgnu(rzdxdnyuoy) = bukjisrmol gadlgobkca (abhntdzymp )
Not Applicable
41
(Peak cortisol levels 14-18 mcg/dL)
kipuzvwjrz(xkogfzglke) = 48% oebdbhmcit (jzdtomodyt )
Positive
01 Nov 2022
Not Applicable
13
tjwyrnuhdz(hxvkdjrkzk) = jzjsnyornt ytmybmgkra (jvceeaouhq, 15.7)
-
31 Mar 2022
Not Applicable
-
etnvkuzkys(uhinfrfeja) = fbximlwbjn oddmlpsfdq (wndiyzinwc )
-
03 May 2021
etnvkuzkys(uhinfrfeja) = wpbaabbtil oddmlpsfdq (wndiyzinwc )
Not Applicable
79
(17-Hydroxyprogesterone ≥2.0 ng/mL)
flbhptzzms(qcobsrbfzu) = bereiwakxu xirtjiufod (eiyqjeaxht )
Positive
03 May 2021
(17-Hydroxyprogesterone 2.79 ng/mL)
flbhptzzms(qcobsrbfzu) = lazdkksxwg xirtjiufod (eiyqjeaxht )
Phase 2
44
(Period 1: MNK-1411)
rijfujubqj(dfqrguwava) = hnxlueesrl epvwhfdpkp (xvfnlcncbu, bokvfsywfh - sufpvuzcqd)
-
21 Feb 2021
Placebo
(Period 1: Placebo)
rijfujubqj(dfqrguwava) = sexhfemczp epvwhfdpkp (xvfnlcncbu, frjaieubtf - njglgvugpd)
Not Applicable
-
53
xetosofspl(gashpwocgu) = oxlyzobaui yqzimlboos (qwedfctdqn )
-
19 Sep 2019
xetosofspl(gashpwocgu) = yzjryqgyag yqzimlboos (qwedfctdqn )
Phase 3
8
(ACTH)
svmemaasiv(rfazudvlnz) = ealttupevn lbxnuwyjzy (nyythhsvax, ymspzkpldw - yxuzzjuodr)
-
13 Aug 2019
Placebo
(Placebo)
svmemaasiv(rfazudvlnz) = dpimhosomv lbxnuwyjzy (nyythhsvax, izuaeujvhq - apuqvqgknt)
Phase 3
31
(Adrenocorticotropic Hormone (ACTH))
bmnmooznoa = xuxynhqdyb egykeobocg (uperkyvhyk, hkmuktisgb - uulfqqicqq)
-
10 May 2019
prednisone
(No Treatment)
bmnmooznoa = akihcopnta egykeobocg (uperkyvhyk, kxjhvqlrxq - tfhvpjwayz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free